No Contracts • Cancel Anytime

On July 22, 2026, the FDA approved zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-fusion positive non-small cell lung cancer (NSCLC) who had already received at least one prior ROS1 tyrosine kinase inhibitor (TKI). Approval was based on the single-arm ARROS-1 trial (NCT05118789; efficacy population n=117), using RECIST v1.1 overall response rate (ORR) and duration of response (DOR) as primary endpoints. For medical students and future physicians,